Metabolic inhibitor screening identifies dihydrofolate reductase as an inducer of the tumor immune escape mediator CD24
ImmunoMedicine · 2022
DOI: 10.1002/imed.1041 ↗Kurz gefasst
Fachartikel in der Zeitschrift ImmunoMedicine, 2022. Verfasst von Austin C Boese und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory, Emory University School of Medicine, Atlanta, Georgia 30322, USA. E…. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, U.S. Department of Defense, National Cancer Institute.
Abstract (Originalsprache)
Immune checkpoint inhibitors (ICIs) have improved the clinical management of some cancer cases, yet patients still fail to respond to immunotherapy. Dysregulated metabolism is a common feature of many cancers, and metabolites are known to modulate functions in cancer cells. To identify potential metabolic pathways involved in anti‐tumor immune response, we employed a metabolic inhibitor‐based drug screen in human lung cancer cell lines and examined expression changes in a panel of immune regulator genes. Notably, pharmacologic inhibition of dihydrofolate reductase (DHFR) downregulated cancer cell expression of cluster of differentiation 24 (CD24), an anti‐phagocytic surface protein. Genetic modulation of DHFR resulted in decreased CD24 expression, whereas tetrahydrofolate, the product of DHFR, enhanced CD24 expression. DHFR inhibition and the consequent CD24 decrease enhanced T cell‐mediated tumor cell killing, whereas replenishment of DHFR or CD24 partially mitigated the immune‐mediated tumor cell killing that resulted from methotrexate treatment in cancer cells. Moreover, publicly available clinical data analyses further revealed the link between DHFR, CD24, and the antitumor immune response in lung cancer patients. Our study highlights a novel connection between folate metabolism and the anti‐tumor immune response and partially interprets how DHFR inhibitors lead to clinical benefits when combined with cancer immunotherapy agents.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory, Emory University School of Medicine, Atlanta, Georgia 30322, USA. Emory University, Atlanta, Georgia 30322, USA.
- These authors contributed equally to this work.
- Current address: Department of Pediatrics, University of California San Francisco, San Francisco, California 94143, USA.
Förderung
- NCI NIH HHS
- U.S. Department of Defense
- National Cancer Institute
Zitieren
APA
Boese, A. C., Hwang, J. S., Young, I., Malin, C. M., Avalos, V., Kang, J., & Kang, S. (2022). Metabolic inhibitor screening identifies dihydrofolate reductase as an inducer of the tumor immune escape mediator CD24. ImmunoMedicine. https://doi.org/10.1002/imed.1041
Vancouver
Boese AC, Hwang JS, Young I, Malin CM, Avalos V, Kang J, et al. Metabolic inhibitor screening identifies dihydrofolate reductase as an inducer of the tumor immune escape mediator CD24. ImmunoMedicine. 2022. doi:10.1002/imed.1041
BibTeX
@article{Boese2022,
author = {Boese, Austin C and Hwang, Jung Seok and Young, Isabelle and Malin, Courteney M and Avalos, Vanessa and Kang, JiHoon and Kang, Sumin},
title = {Metabolic inhibitor screening identifies dihydrofolate reductase as an inducer of the tumor immune escape mediator CD24},
journal = {ImmunoMedicine},
year = {2022},
doi = {10.1002/imed.1041}
}
EUVIMED